Welcome to our dedicated page for BIODESIX SEC filings (Ticker: BDSX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Biodesix, Inc. (BDSX) SEC filings page on Stock Titan brings together the company’s official disclosures as a Nasdaq-listed diagnostic solutions company. Through its reports to the U.S. Securities and Exchange Commission, Biodesix provides detail on its diagnostic testing and development services businesses, capital structure, and material corporate events.
Investors can use this page to access current and historical filings such as annual reports on Form 10-K and quarterly reports on Form 10-Q, which describe revenue from Lung Diagnostics and Development Services, operating metrics, and risk factors relevant to a diagnostics and health care business. These core filings typically discuss Biodesix Diagnostic Tests marketed as Nodify Lung® Nodule Risk Assessment and IQLung® Cancer Treatment Guidance, as well as the company’s work with biopharmaceutical and life sciences partners.
Biodesix also files Forms 8-K to report specific material events. Recent 8-K filings document actions such as a one-for-twenty reverse stock split of the company’s common stock, the related amendment to its certificate of incorporation, elimination of a preferred stock series, and confirmation that the company regained compliance with Nasdaq’s minimum bid price requirement. Other 8-Ks furnish press releases announcing quarterly financial and operating results.
On this page, users can review insider and capital structure-related filings when available, including information about changes to equity, preferred stock designations, and other securities. These documents help clarify how corporate actions affect common stockholders and outstanding awards or warrants.
Stock Titan enhances access to Biodesix filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify discussions of revenue composition, diagnostic and development services, stock listing matters, and significant corporate changes. Real-time updates from the EDGAR system ensure that new Biodesix 10-K, 10-Q, 8-K, and related filings appear promptly, while AI-generated overviews provide a starting point for deeper review of the full regulatory text.
Biodesix Inc. director Hany Massarany reported new equity awards. On January 2, 2026, he received 7,484 restricted stock units (RSUs), each representing one share of Biodesix common stock. These RSUs vest in four equal installments on March 31, June 30, September 30 and December 31, 2026, generally conditioned on continued service.
Some of the RSUs are deferred, with the underlying shares to be issued after his separation from service. Massarany was also granted stock options for 6,354 shares at an exercise price of $6.46 per share, vesting in four substantially equal installments on the same 2026 dates, also generally subject to continued service.
Biodesix Inc. director and 10% owner Lawrence T. Kennedy Jr. reported awards of restricted stock units (RSUs) and stock options dated January 2, 2026. He received 5,443 RSUs, each representing a right to one share of common stock, which vest in four equal installments on March 31, June 30, September 30 and December 31, 2026, generally contingent on continued service and with no expiration date. These include deferred RSUs that will be settled in shares after his separation from service. He also received stock options for 6,354 shares at an exercise price of $6.46 per share, vesting on the same quarterly 2026 schedule and expiring on January 1, 2036.
Biodesix Inc. reported an insider stock option grant to its Chief Commercial Officer, Kieran O'Kane. On January 2, 2026, O'Kane was awarded stock options representing the right to buy 27,000 shares of Biodesix common stock at an exercise price of $6.46 per share. These options were granted at no cost to him and are held directly.
The option grant has a long-term structure. It vests in forty-eight substantially equal monthly installments starting January 2, 2026, generally requiring O'Kane to continue serving at the company through each vesting date. The options are scheduled to expire on January 1, 2036 if not exercised.
Biodesix, Inc. reported an insider equity award to a senior executive. Chief Accounting Officer Chris Vazquez was granted stock options covering 12,000 shares of Biodesix common stock on January 2, 2026.
The options have an exercise price of $6.46 per share and expire on January 1, 2036. They vest in forty-eight equal monthly installments starting January 2, 2026, generally requiring Vazquez to remain in service through each vesting date. Following this grant, Vazquez beneficially owns 12,000 stock options directly.
Biodesix (BDSX) reported a routine insider transaction for Chief Accounting Officer Chris Vazquez. On 11/10/2025, 31 shares of common stock were acquired upon the vesting of restricted stock units, adjusted for the one-for-twenty reverse stock split effective September 15, 2025. To cover taxes upon vesting, 13 shares were automatically sold at $7.62. Following these transactions, Vazquez directly owned 936 shares. Each RSU represents one share of common stock, and the RSUs vest in sixteen successive quarterly installments measured from February 8, 2022 and have no expiration date.
Biodesix (BDSX) insider transaction: Chief Development Officer Gary Pestano reported RSU vesting and a small tax sale on 11/10/2025. A total of 69 shares were issued upon RSU settlement (code M), and 23 shares of common stock were sold at $7.62 to cover taxes tied to the vesting.
Following these transactions, Pestano beneficially owned 7,939 shares directly. The filing notes all share figures reflect the one‑for‑twenty reverse stock split effective September 15, 2025, and that each RSU represents one share of common stock.
Biodesix (BDSX) Chief Commercial Officer Kieran O’Kane reported RSU vesting and a related sale on 11/10/2025. He acquired 75 shares of common stock upon RSU vesting (code M) and sold 25 shares at $7.62 to cover taxes upon vesting. Following these transactions, he directly owned 7,362 shares of common stock and held 73 RSUs.
The filing notes all figures reflect the 1-for-20 reverse stock split effective September 15, 2025. The RSUs vest in sixteen successive quarterly installments measured from February 8, 2022, subject to continued service. Prior ownership includes 309 shares purchased under the Employee Stock Purchase Plan on September 2, 2025.
Biodesix (BDSX) disclosed insider activity by its President & CEO and Director, Scott Hutton. On 11/10/2025, 611 shares of Common Stock were acquired upon RSU vesting, followed by an automatic sale of 189 shares at $7.62 to cover taxes. Following these transactions, the reporting person directly beneficially owned 37,311 shares.
The amounts reflect the one-for-twenty reverse stock split effective September 15, 2025. After the vesting event, 610 RSUs remained outstanding, with RSUs vesting in successive quarterly installments measured from February 8, 2022.
Biodesix (BDSX) reported an insider transaction by its CFO, Secretary & Treasurer, Robin Harper Cowie. On 11/10/2025, 158 shares of Common Stock were acquired upon the vesting of restricted stock units, adjusted for the one-for-twenty reverse stock split effective September 15, 2025. To cover taxes from the vesting, 50 shares were sold at $7.62. Following these transactions, the reporting person beneficially owned 13,147 shares directly.
Biodesix, Inc. (BDSX) filed its Q3 2025 10‑Q reporting higher revenue and continued losses. Revenue was $21.8 million for the quarter and $59.7 million year‑to‑date, while the quarterly net loss was $8.7 million and the nine‑month net loss was $31.3 million.
Cash and cash equivalents were $16.6 million and borrowings carried at $47.1 million. The company drew a $10.0 million Tranche C loan under its Perceptive Term Loan Facility and raised $5.0 million gross through its at‑the‑market program. Stockholders’ equity shifted to a deficit of $1.7 million.
Biodesix effected a 1‑for‑20 reverse stock split on September 15, 2025 and subsequently regained Nasdaq minimum bid price compliance. Shares outstanding were 7,955,685 as of October 28, 2025.
FAQ
What is the current stock price of BIODESIX (BDSX)?
What is the market cap of BIODESIX (BDSX)?
